

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: 09.02.83

(21) Application number: 79302169.2

(22) Date of filing: 10.10.79

(51) Int. Cl.³: **C 07 C 93/26,**
C 07 C 93/06,
A 61 K 31/215

(54) **1-Acyloxyphenyl-1,2-diphenylalkene derivatives, processes for their manufacture and a pharmaceutical composition containing these derivatives.**

(30) Priority: 07.11.78 GB 4343078

(43) Date of publication of application:
28.05.80 Bulletin 80/11

(45) Publication of the grant of the patent:
09.02.83 Bulletin 83/6

(84) Designated Contracting States:
AT BE CH DE FR GB IT LU NL SE

(56) References cited:
AT - B - 345 804
DE - A - 1 493 855
DE - A - 2 807 599
GB - A - 945 864
US - A - 2 914 564
US - A - 3 237 200

(73) Proprietor: **IMPERIAL CHEMICAL INDUSTRIES PLC**
Imperial Chemical House Millbank
London SW1P 3JF (GB)

(72) Inventor: **Richardson, Dora Nellie**
3 Silverdale Road
Gatley, Cheshire (GB)

(74) Representative: **Slatcher, Reginald Peter et al,**
Imperial Chemical Industries PLC Legal
Department: Patents Thames House North
Millbank
London SW1P 4QG (GB)

EP 0 011 372 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).


Courier Press, Leamington Spa, England

BEST AVAILABLE COPY

0011 372

1-Acyloxyphenyl-1,2-diphenylalkene derivatives, processes for their manufacture and a pharmaceutical composition containing these derivatives

This invention relates to triphenylalkene derivatives which possess anti-oestrogenic activity. According to the invention there is provided an alkene derivative of the formula:—



wherein either R¹ is a hydrogen atom or a lower alkyl radical and R² is a lower alkyl radical, or R¹ and R² are joined together with the adjacent nitrogen atom to form a heterocyclic radical, n is 2, 3, 4, 5 or 6; R³ is a halogen atom or a lower alkyl radical; R⁴ is a hydrogen or halogen atom, or a hydroxy or lower alkyl or lower alkoxy radical, or is the buta-1,3-dienyl radical such that together with the benzene ring it forms a naphthyl radical, or R⁴ has the formula —OCOR⁵; and R⁵ is an alkyl radical of 1 to 10 carbon atoms or an alkoxyalkyl radical of 2 to 10 carbon atoms, or R⁵ has the formula



wherein m is 0, 1, 2, 3 or 4, wherein R⁶ is a hydrogen or halogen atom or a cyano, lower alkyl or lower alkoxy radical and wherein p is 1, 2 or 3; or R⁵ has the formula —NHR⁷, wherein R⁷ is an alkyl radical of 1 to 10 carbon atoms or R⁷ has the formula



wherein m, p and R⁶ have the meanings stated above; or a pharmaceutically-acceptable acid-addition salt thereof.

It is clear that a compound of the invention can exist in the form of a *cis* or a *trans* isomer in which the designation *cis* or *trans* refers to the relative positions of the acyloxyphenyl radical, and the phenyl radical bearing the group R⁴, about the double bond. The *cis* and *trans* isomers may be distinguished by the magnetic resonance signals of the protons in the —OCH₂— group of the —O(CH₂)_nNR¹R² side-chain, the signals of these protons in the *cis* isomers occurring at lower field than of those in the corresponding *trans* isomers. This invention includes both *cis* and *trans* isomers and mixtures thereof which possess the above properties, it being a matter of common general knowledge how to separate *cis* and *trans* isomers and how to determine their anti-oestrogenic and oestrogenic activity.

R¹, R², R³, R⁴ or R⁶ when it is a lower alkyl radical is an alkyl radical of 1—4 carbon atoms, for example a methyl, ethyl, n-propyl, isopropyl or a butyl radical.

R¹ and R² when they are joined together with the adjacent nitrogen atom to form a heterocyclic radical form a 5- or 6- membered nitrogen-containing heterocyclic radical optionally including an oxygen or sulphur atom as a second hetero-atom, for example a pyrrolidino, piperidino or morpholino radical.

A particularly suitable value for R³, R⁴ or R⁶ when it is a halogen atom is, for example, a fluorine, chlorine or bromine atom.

R⁴ or R⁶ when it is a lower alkoxy radical is an alkoxy radical of 1—4 carbon atoms, for example a methoxy or ethoxy radical.


A particularly suitable value for R⁵ when it is an alkyl or alkoxyalkyl radical is, for example, the methyl, ethyl, isopropyl, hexyl, decyl or methoxymethyl radical.

A particularly suitable salt is, for example a hydrochloride, sulphate, phosphate, acetate, tartrate or citrate.

A preferred compound of the invention has formula I given above wherein R¹ and R² are both the same lower alkyl radical, preferably the methyl or ethyl radical and especially the methyl radical, wherein R³ is a lower alkyl radical, preferably the methyl, ethyl or n-propyl radical and especially the ethyl radical, wherein R⁴ is hydrogen or is a halogen atom or a lower alkyl or lower alkoxy radical, preferably the fluorine, chlorine or bromine atom or the methyl, ethyl or methoxy radical, and especially such a radical in the 4-position, wherein R⁵ is the methyl, ethyl, isopropyl, t-butyl, methoxymethyl, phenyl, 2-tolyl, 4-tolyl, 2-ethylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, 4-cyanophenyl, benzyl, methylamino, propylamino or anilino radical, and wherein n is 2, 3, 4 or 5, preferably 2, or is a pharmaceutically-acceptable acid-addition salt thereof. In general, *trans*-isomers are more active than the corresponding *cis*-isomers.


Particular compounds of the invention are set out in the Examples, and preferred compounds are 1-(*p*- β -dimethylaminoethoxyphenyl)-*trans*-1-*p*-acetoxyphenyl-2-*p*-tolylbut-1-ene, 1-(*p*- β -dimethylaminoethoxyphenyl)-*trans*-1-*p*-acetoxyphenyl-2-phenylbut-1-ene, 1-(*p*- β -dimethylaminoethoxyphenyl)-*trans*-1-*p*-benzoyloxyphenyl-2-phenylbut-1-ene, 1-(*p*- β -dimethylaminoethoxyphenyl)-*trans*-1-*p*-propionyloxyphenyl-2-phenylbut-1-ene, 1-(*p*- β -dimethylaminoethoxyphenyl)-*trans*-1-*p*-acetoxyphenyl-2-*p*-ethylphenylbut-1-ene and 1-(*p*- β -dimethylaminoethoxyphenyl)-*trans*-1-*p*-benzoyloxyphenyl-2-*p*-tolylbut-1-ene.

A compound of formula I may be obtained by the processes which are applicable to the manufacture of analogous compounds. Thus, for example, an alkene derivative of the formula:—



wherein R¹, R², R³, R⁴ and n have the meanings stated above (which alkene derivatives are mostly described in European Specification No. 0,002,097 or are otherwise known compounds, or may be obtained by analogous methods to those known or described in said Specification) may be acylated with an acylating derivative obtained from an acid of the formula R⁵COOH; wherein R⁵ has the meaning stated above, or, when R⁵ has the formula —NHR⁷, may be reacted with an isocyanate of the formula R⁷NCO.

A suitable acylating derivative is, for example, an acyl chloride or an acid anhydride. Alternatively, an alkanol of the formula:—



wherein R¹, R², R³, R⁴, R⁵ and n have the meanings stated above, may be dehydrated with an acid, for example hydrochloric acid, conveniently in a solvent, for example ethanol, at a temperature of from 20°C. to 80°C.

The alkene derivative so obtained may be in the form of a mixture of the *cis* and *trans* isomers. If desired, the individual isomers may be obtained by fractional crystallisation of the mixture, or by chromatography.

The starting material of formula III may be obtained by the acylation with an acylating derivative, for example an acyl chloride or acid anhydride, obtained from an acid of the formula R⁵COOH, wherein R⁵ has the meaning stated above, of the corresponding hydroxy compound (which hydroxy compounds are mostly described in European Specification No. 0,002,097, or are known compounds, or may be obtained by analogous methods to those known or described in said Specification).

An alkene derivative of the invention in free base form may be converted into an acid-addition said thereof by reaction with an acid.

The anti-oestrogenic activity of a compound of formula I has been demonstrated by its effect in preventing implantation of the fertilised ovum when administered orally to rats on day 4 of pregnancy. In this test, each of the compounds showed substantial activity at a dose of 0.2 mg./kg. and a preferred compound showed activity at a dose of 0.01 mg./kg. this compound therefore being substantially more active than tamoxifen. Anti-oestrogenic activity can also be demonstrated by inhibition of oestradiol-induced vaginal cornification in ovariectomised rats, and by inhibition of uterine growth when given concomitantly with an oestrogen to immature female rats.

The weak oestrogenic activity of a compound of formula I has been demonstrated by its effect in producing cornified vagina smears in spayed rats when administered orally once daily for 3 days. In this test, each of the compounds showed oestrogenic activity only at a dose substantially greater than that required to produce anti-oestrogenic effects.

A compound with the above pharmacological properties is of value in the treatment of the same conditions in which tamoxifen is beneficial, in particular, in the treatment of anovulatory infertility and in the treatment of breast tumours.

When used to produce an anti-oestrogenic effect in warm blooded animals, a typical daily dose is from 0.05 to 1 mg./kg. administered orally or by injection. In man this is equivalent to an oral dose of from 5—80 mg./day. In use, tamoxifen has been administered orally at doses of from 20—80 mg./day for the treatment of anovulatory infertility, and at doses from 10—40 mg./day for the treatment of breast tumors. A similar regime is appropriate for the administration of a compound of formula I, most conveniently in the form of a pharmaceutical composition.

According to a further feature of the invention, there is provided a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable acid-addition salt thereof, together with a pharmaceutically acceptable diluent or carrier.

The composition may be in a form suitable for oral or parenteral administration. A tablet or capsule is a particularly convenient form for oral administration, and such a composition may be made by conventional methods and contain conventional excipients. Thus a tablet could contain diluents, for example mannitol or maize starch, disintegrating agents, for example, alginic acid, binding agents, for example methylcellulose, and lubricating agents, for example magnesium stearate.

A composition for oral administration may conveniently contain from 5—50 mg. of a compound of formula I, preferably 5—20 mg.

The invention is illustrated but not limited by the following Examples:—

Example 1

A mixture of 1-(*p*- β -dimethylaminoethoxyphenyl)-*trans*-1-*p*-hydroxyphenyl-2-phenylbut-1-ene (1.0 g.), acetic anhydride (25 ml.) and anhydrous sodium acetate (0.5 g.) is heated under reflux for 30 minutes, cooled and poured into ice-water. The mixture is made alkaline with aqueous ammonium hydroxide solution and extracted with ethyl acetate. The extract is dried, evaporated to dryness and the residue is crystallised from petroleum ether (b.p. 80—100°C). There is thus obtained 1-(*p*- β -dimethylaminoethoxyphenyl)-*trans*-1-*p*-acetoxyphenyl-2-phenylbut-1-ene, m.p. 108—110°C.

The process described above is repeated using the appropriate but-1-ene derivative and the appropriate acid anhydride, and there are thus obtained the compounds of Formula I (in all of which R¹ and R² are both methyl, n is 2 and R³ is ethyl) described in the following table:—

R ⁴	R ⁵	isomer	m.p.(°C.)
H	methyl	cis	70—74
H	ethyl	trans	91—93
4-methyl	methyl	trans	106—108
4-methyl	methyl	cis	68—70
4-acetoxy	methyl	trans	96—99
4-ethyl	methyl	trans	74
4-ethyl	methyl	cis	78

0011372

Example 2

Benzoyl chloride (0.3 ml.) is added to a cooled solution of 1-(*p*- β -dimethylaminoethoxyphenyl)-*trans*-1-*p*-hydroxyphenyl-2-phenylbut-1-ene (0.4 g.) in pyridine (3 ml.) and the mixture is kept at 0°C. for 17 hours and then poured into water. The mixture is extracted with ether and the extract is dried and evaporated to dryness. The residue is dissolved in petroleum ether (b.p. 80—100°C.) and the solution is allowed to evaporate slowly. The residue crystallises and consists of 1-(*p*- β -dimethylaminoethoxy-phenyl)-*trans*-1-*p*-benzoyloxyphenyl-2-phenylbut-1-ene, m.p. 96—98°C.

The process described above is repeated using the appropriate acyl chloride and the appropriate 1-*p*-dialkylaminoalkoxy-1-*p*-hydroxyphenyl-2-phenylalk-1-ene derivative as starting materials and there are thus obtained the compounds described in the following tables:—

Table 1: Compounds have Formula I wherein R¹ and R² are both methyl, n is 2, R³ is ethyl and R⁴ is hydrogen:—

R ⁵	Isomer	m.p.(°C.)
phenyl	cis	140—142
2-tolyl	trans	115—117
4-tolyl	trans	108—110
4-tolyl	cis	109—111
4-methoxyphenyl	trans	117—118
4-methoxyphenyl	cis	118
2-chlorophenyl	trans	108—110
3-chlorophenyl	trans	76—78
4-chlorophenyl	trans	80—82
4-chlorophenyl	cis	90—92
4-bromophenyl	trans	94—96
4-bromophenyl	cis	94
2,6-dichlorophenyl	trans	135—137
isopropyl	trans	104—107

Table 2: Compounds have Formula I wherein n is 2 and R⁵ is unsubstituted phenyl.

R ¹	R ²	R ³	R ⁴	Isomer	m.p.(°C.)
methyl	methyl	isopropyl	H	trans	120—124
methyl	methyl	ethyl	2-methyl	trans	125
methyl	methyl	ethyl	4-methyl	trans	113—115
methyl	methyl	ethyl	4-ethyl	trans	173
methyl	methyl	ethyl	4-ethyl	cis	95
methyl	methyl	ethyl	3-chloro	trans	(oil)
ethyl	ethyl	ethyl	4-methoxy	trans	99—101

0011 372

Example 3

A solution of 1-(*p*- β -dimethylaminoethoxyphenyl)-*trans*-1-*p*-hydroxyphenyl-2-phenylbut-1-ene (0.77 g.) in tetrahydrofuran (15 ml.) is added to a stirred suspension of sodium hydride (0.5 g.) in tetrahydrofuran (10 ml.) and the mixture is stirred at laboratory temperature for 30 minutes. The solution is removed by pipette from the excess of sodium hydride and to this solution is added a solution of 2-ethylbenzoyl chloride (0.45 g.) in tetrahydrofuran (3 ml.). The mixture is stirred at laboratory temperature for 15 minutes, diethyl ether (30 ml.) is added and the solution is washed with saturated aqueous sodium bicarbonate solution and then with water. The ethereal solution is dried and evaporated to dryness and the residue is crystallised from hexane. There is thus obtained 1-(*p*- β -dimethylaminoethoxyphenyl)-*trans*-1-(2-ethylbenzoyloxyphenyl)-2-phenylbut-1-ene, m.p. 77—78°C.

The process described above is repeated using the appropriate acid chloride, in place of 2-ethylbenzoyl chloride, and there are thus obtained the compounds of formula I (in all of which R¹ and R² are both methyl, n is 2, R³ is ethyl and R⁴ is hydrogen) described in the following table:—

R ⁵	isomer	m.p.(°C.)
2-tolyl	cis	95—98
2,6-dichlorophenyl	trans	126—127
4-cyanophenyl	trans	172—174
methoxymethyl	trans	81—83
methoxymethyl	cis	70—72
benzyl	cis	84—86
benzyl	trans	100—102
t-butyl	trans	118—119

Example 4

A solution of phenyl isocyanate (0.298 g.) in dry *N,N*-dimethylformamide (2 ml.) is added during 10 minutes to a stirred solution of 1-(*p*- β -dimethylaminoethoxyphenyl)-*trans*-1-*p*-hydroxyphenyl-2-phenylbut-1-ene (0.774 g.) and triethylamine (0.02 g.) in dry *N,N*-dimethylformamide (5 ml.) which is cooled to 0°C. The mixture is stirred for 15 minutes at 0°C. and then for 17 hours at laboratory temperature, diethyl ether (30 ml.) is added and the mixture is washed three times with water (20 ml. each time), dried and evaporated to dryness. The residue is crystallised from cyclohexane and the solid product dissolved in methylene chloride. The mixture is filtered, the filtrate is evaporated to dryness and the residue is stirred with cold methanol. The mixture is filtered and there is thus obtained as solid residue 1-(*p*- β -dimethylaminoethoxyphenyl)-*trans*-1-(*p*-*N*-phenylcarbamoxyloxyphenyl)-2-phenylbut-1-ene, m.p. 145—146°C.

The process described above is repeated except that methyl or propyl isocyanate is used in place of phenyl isocyanate. There are thus obtained the compounds of formula I (in all of which R¹ and R² are both methyl, n is 2, R³ is ethyl and R⁴ is hydrogen) described in the following table:—

R ⁵	isomer	m.p.(°C.)
methylamino	trans	130—131
propylamino	trans	98—100


Claims for the Contracting States: BE CH DE FR GB IT LU NL SE

1. An alkene derivative of the formula:—

5


10

15




wherein either R¹ is a hydrogen atom or an alkyl radical of 1—4 carbon atoms and R² is an alkyl radical of 1—4 carbon atoms, or R¹ and R² are joined together with the adjacent nitrogen atom to form a 5- or 6-membered heterocyclic radical; n is 2, 3, 4, 5 or 6; R³ is a halogen atom or an alkyl radical of 1—4 carbon atoms; R⁴ is a hydrogen or halogen atom, or a hydroxy or alkyl or alkoxy radical each of 1—4 carbon atoms, or is the buta-1,3-dienyl radical such that together with the benzene ring it forms a naphthyl radical, or R⁴ has the formula —OCOR⁵; and R⁵ is an alkyl radical of 1 to 10 carbon atoms or an alkoxyalkyl radical of 2 to 10 carbon atoms, or R⁵ has the formula

25



wherein m is 0, 1, 2, 3 or 4, wherein R⁶ is a hydrogen or halogen atom or a cyano, or alkyl or alkoxy radical each of 1—4 carbon atoms, and wherein p is 1, 2 or 3; or R⁵ has the formula —NHR⁷, wherein R⁷ is an alkyl radical of 1 to 10 carbon atoms or R⁷ has the formula

35



wherein m, p and R⁶ have the meanings stated above, or a pharmaceutically-acceptable acid-addition salt thereof.

2. An alkene derivative as claimed in claim 1 wherein R¹ and R² are both methyl or both ethyl radicals, R³ is the methyl, ethyl or propyl radical, R⁴ is the hydrogen, fluorine, chlorine or bromine atom or the methyl, ethyl or methoxy radical, R⁵ is the methyl, ethyl, isopropyl, t-butyl, methoxymethyl, phenyl, 2-tolyl, 4-tolyl, 2-ethylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxyphenyl, 4-cyanophenyl, benzyl, methylamino, propylamino or anilino radical and wherein n is 2, 3, 4 or 5, or a pharmaceutically acceptable acid-addition salt thereof.

3. An alkene derivative as claimed in claim 2 wherein R¹ and R² are both methyl radicals, R³ is the ethyl radical, R⁴ is the hydrogen atom or the chlorine atom or the methyl or ethyl radical in the 4-position, wherein R⁵ is the methyl, ethyl, isopropyl or phenyl radical and wherein n is 2, or a pharmaceutically-acceptable acid-addition salt thereof.

4. The compound 1-(p-β-dimethylaminoethoxyphenyl)-trans-1-p-acetoxyphenyl-2-p-tolylbut-1-ene, 1-(p-β-dimethylaminoethoxyphenyl)-trans-1-p-acetoxyphenyl-2-phenylbut-1-ene, 1-(p-β-dimethylaminoethoxyphenyl)-trans-1-p-benzoyloxyphenyl-2-phenylbut-1-ene or 1-(p-β-dimethylaminoethoxyphenyl)-trans-1-p-propionyloxyphenyl-2-phenylbut-1-ene.


5. The compound 1-(p-β-dimethylaminoethoxyphenyl)-trans-1-p-acetoxyphenyl-2-p-ethylphenylbut-1-ene or 1-(p-β-dimethylaminoethoxyphenyl)-trans-1-p-benzoyloxyphenyl-2-p-tolylbut-1-ene.

6. A process for the manufacture of an alkene derivative, claimed in any of claims 1 to 5, or a pharmaceutically-acceptable acid-addition salt thereof, which comprises either

(a) the acylation of an alkene derivative of the formula:—

65


0011 372



(II)

wherein R^1 , R^2 , R^3 , R^4 and n have the meanings stated in claim 1 with an acylating derivative obtained from an acid of the formula R^5COOH , wherein R^5 has the meaning stated in claim 1, or, when R^5 has the formula $-\text{NHR}^7$, the reaction of said alkene derivative with an isocyanate of the formula R^7NCO ; or

(b) the dehydration of an alkanol of the formula:—




(III)

wherein R^1 , R^2 , R^3 , R^4 , R^5 and n have the meanings stated above, with an acid whereafter the alkene derivative may be separated into its *cis*- and *trans*-isomers; and whereafter an alkene derivative in free base form may be converted into an acid-addition salt thereof by reaction with an acid.

7. A pharmaceutical composition which comprises an alkene derivative or a pharmaceutically-acceptable acid-addition salt thereof claimed in any of claims 1 to 5, together with a pharmaceutically-acceptable diluent or carrier.


Claims for the Contracting State: AT

1. A process for the manufacture of an alkene derivative of the formula:—




(I)

wherein either R^1 is a hydrogen atom or an alkyl radical of 1—4 carbon atoms and R^2 is an alkyl radical of 1—4 carbon atoms, or R^1 and R^2 are joined together with the adjacent nitrogen atom to form a 5- or 6-membered heterocyclic radical; n is 2, 3, 4, 5 or 6; R^3 is a halogen atom or an alkyl radical of 1—4 carbon atoms; R^4 is a hydrogen or halogen atom, or a hydroxy or alkyl or alkoxy radical each of 1—4 carbon atoms, or is the buta-1,3-dienyl radical such that together with the benzene ring it forms a naphthyl radical, or R^4 has the formula $-\text{OCOR}^5$; and R^5 is an alkyl radical of 1 to 10 carbon atoms or an alkoxyalkyl radical of 2 to 10 carbon atoms, or R^5 has the formula




wherein m is 0, 1, 2, 3 or 4, wherein R^6 is a hydrogen or halogen atom or a cyano, or alkyl or alkoxy radical each of 1—4 carbon atoms and wherein p is 1, 2 or 3 or R^6 has the formula $-\text{NHR}^7$, wherein R^7 is an alkyl radical of 1 to 10 carbon atoms or R^7 has the formula

0011 372




wherein m, p and R^6 have the meanings stated above, or a pharmaceutically-acceptable acid-addition salt thereof, characterised by either

(a) the acylation of an alkene derivative of the formula:—




wherein R^1 , R^2 , R^3 , R^4 and n have the meanings stated above with an acylating derivative obtained from an acid of the formula $R^5\text{COOH}$, wherein R^5 has the meaning stated above, or, when R^5 has the formula $-\text{NHR}^7$, the reaction of said alkene derivative with an isocyanate of the formula $R^7\text{NCO}$; or

(b) the dehydration of an alkanol of the formula:—




wherein R^1 , R^2 , R^3 , R^4 , R^5 and n have the meanings stated above, with an acid, whereafter the alkene derivative may be separated into its *cis*- and *trans*-isomers; and whereafter an alkene derivative in free base form may be converted into an acid-addition salt thereof by reaction with an acid.

2. A process for the manufacture of an alkene derivative of the formula:—




wherein R^1 and R^2 are both the same alkyl radical of 1—4 carbon atoms, wherein R^3 is an alkyl radical of 1—4 carbon atoms, wherein R^4 is hydrogen or is a halogen atom or an alkyl radical of 1—4 carbon atoms, wherein R^5 is methyl, ethyl, isopropyl or phenyl and wherein n is 2, 3, 4 or 5, or a pharmaceutically-acceptable acid-addition salt thereof, characterised by the acylation of an alkene derivative of the formula:—



wherein R^1 , R^2 , R^3 , R^4 and n have the meanings stated above, with an acylating derivative obtained from an acid of the formula $R^5\text{COOH}$, wherein R^5 has the meaning stated above, whereafter the alkene derivative may be separated into its *cis*- and *trans*-isomers.


6 Patentansprüche für die Vertragsstaaten: BE CH DE FR GB IT LU NL SE

1. Alkenderivat der Formel



- 20 worin entweder R^1 für ein Wasserstoffatom oder ein Alkylradikal mit 1 bis 4 Kohlenstoffatomen steht und R^2 für ein Alkylradikal mit 1 bis 4 Kohlenstoffatomen steht oder R^1 und R^2 miteinander verbunden sind und mit dem benachbarten Stickstoffatom ein 5- oder 6-gliedriges heterocyclisches Radikal bilden; n für 2, 3, 4, 5 oder 6 steht; R^3 für ein Halogenatom oder ein Alkylradikal mit 1 bis 4 Kohlenstoffatomen steht; R^4 für ein Wasserstoff- oder Halogenatom oder ein Hydroxy- oder Alkyl- oder Alkoxyradikal mit jeweils 1 bis 4 Kohlenstoffatomen oder das Buta-1,3-dienylradikal, welches gemeinsam mit dem Benzolring ein Naphthylradikal bildet, steht oder R^4 die Formel $-\text{OCOR}^5$ aufweist; und R^5 für ein Alkylradikal mit 1 bis 10 Kohlenstoffatomen oder ein Alkoxyalkylradikal mit 2 bis 10 Kohlenstoffatomen steht oder R^5 die Formel


30



35

- aufweist, wobei m für 0, 1, 2, 3, oder 4 steht, R^6 für ein Wasserstoff- oder Halogenatom oder ein Cyano- oder ein Alkyl- oder Alkoxyradikal mit jeweils 1 bis 4 Kohlenstoffatomen steht und p für 1, 2, oder 3 steht, oder R^6 die Formel $-\text{NHR}^7$ aufweist, worin R^7 für ein Alkylradikal mit 1 bis 10 Kohlenstoffatomen steht, oder R^7 die Formel

40



45

- aufweist, wobei m , p und R^6 die oben angegebenen Bedeutungen besitzen; oder ein pharmazeutisch zulässiges Säureadditionssalz davon.

2. Alkenderivat nach Anspruch 1, worin R^1 und R^2 beide für Methyl- oder beide für Äthylradikale stehen, R^3 für das Methyl-, Äthyl- oder Propylradikal steht, R^4 für das Wasserstoff-, Fluor-, Chlor- oder Bromatom oder das Methyl-, Äthyl-, oder Methoxyradikal steht R^5 für das Methyl-, Äthyl-, Isopropyl-, t-Butyl-, Methoxymethyl-, Phenyl-, 2-Tolyl-, 4-Tolyl-, 2-Äthylphenyl-, 2-Chlorophenyl-, 3-Chlorophenyl-, 4-Chlorophenyl-, 4-Bromophenyl-, 4-Methoxyphenyl-, 4-Cyanophenyl-, Benzyl-, Methylamino-, Propylamino- oder Anilinoradikal steht und n für 2, 3, 4 oder 5 steht, oder ein pharmazeutisch zulässiges Säureadditionssalz davon.

55


3. Alkenderivat nach Anspruch 2, worin R^1 und R^2 beide für Methylradikale stehen, R^3 für das Äthylradikal steht, R^4 für das Wasserstoffatom oder das Chloratom oder das Methyl- oder Äthylradikal in der 4-Stellung steht, R^5 für das Methyl-, Äthyl-, Isopropyl- oder Phenylradikal steht und n für 2 steht, oder ein pharmazeutisch zulässiges Säureadditionssalz davon.

4. Die Verbindung 1-(p-β-Dimethylaminoäthoxyphenyl)-trans-1-p-acetoxyphenyl-2-p-tolylbut-1-en, 1-(p-β-Dimethylaminoäthoxyphenyl)-trans-1-p-acetoxyphenyl-2-phenylbut-1-en, 1-(p-β-Dimethylaminoäthoxyphenyl)-trans-1-p-benzoyloxyphenyl-2-phenylbut-1-en oder 1-(p-β-Dimethylaminoäthoxyphenyl)-trans-1-p-propionyloxyphenyl-2-phenylbut-1-en.


5. Die Verbindung 1-(p-β-Dimethylaminoäthoxyphenyl)-trans-1-p-acetoxyphenyl-2-p-äthylphenylbut-1-en oder 1-(p-β-Dimethylaminoäthoxyphenyl)-trans-1-p-benzoyloxyphenyl-2-p-tolylbut-1-en.

0011372

6. Verfahren zur Herstellung eines Alkenderivats nach einem der Ansprüche 1 bis 5 oder eines pharmazeutisch zulässigen Säureadditionssalzes davon, dadurch gekennzeichnet, daß entweder
(a) ein Alkenderivat der Formel



20 worin R^1 , R^2 , R^3 , R^4 und n die in Anspruch 1 angegebenen Bedeutungen besitzen, mit einem acylierenden Derivat acyliert wird, das sich von einer Säure der Formel R^5COOH ableitet, worin R^5 die in Anspruch 1 angegebene Bedeutung besitzt, oder, wenn R^5 die Formel $-\text{NHR}^7$ besitzt, dieses Alkenderivat mit einem Isocyanat der Formel R^7NCO umgesetzt wird; oder
(b) ein Alkanol der Formel




35 worin R^1 , R^2 , R^3 , R^4 , R^5 und n die oben angegebenen Bedeutungen besitzen, mit einer Säure dehydratisiert wird;
worauf das Alkenderivat in cis- und trans-Isomere getrennt werden kann; und
worauf ein Alkenderivat in der freien Basenform durch Umsetzung mit einer Säure in ein Säureadditionssalz umgewandelt werden kann.

40 7. Pharmazeutische Zusammensetzung, welche ein Alkenderivat oder ein pharmazeutisch zulässiges Säureadditionssalz davon nach einem der Ansprüche 1 bis 5 zusammen mit einem pharmazeutisch zulässigen Verdünnungsmittel oder Trägermittel enthält.

Patentansprüche für den Vertragsstaat: AT


1. Verfahren zur Herstellung eines Alkenderivats der Formel




60 worin entweder R^1 für ein Wasserstoffatom oder ein Alkylradikal mit 1 bis 4 Kohlenstoffatomen steht und R^2 für ein Alkylradikal mit 1 bis 4 Kohlenstoffatomen steht oder R^1 und R^2 miteinander verbunden sind und mit dem benachbarten Stickstoffatom ein 5- oder 6-gliedriges heterocyclisches Radikal bilden;
 n für 2, 3, 4, 5 oder 6 steht; R^3 für ein Halogenatom oder ein Alkylradikal mit 1 bis 4 Kohlenstoffatomen steht; R^4 für ein Wasserstoff- oder Halogenatom oder ein Hydroxy- oder Alkyl- oder Alkoxyradikal mit jeweils 1 bis 4 Kohlenstoffatomen oder das Buta-1,3-dienylradikal, welches gemeinsam mit dem Benzolring ein Naphthylradikal bildet, steht oder R^4 die Formel $-\text{OCOR}^5$ aufweist; und R^5 für ein Alkylradikal mit 1 bis 10 Kohlenstoffatomen oder ein Alkoxyalkylradikal mit 2 bis 10 Kohlenstoffatomen steht oder R^5 die Formel

65


0 011 372




5 aufweist, wobei m für 0, 1, 2, 3 oder 4 steht, R^6 für ein Wasserstoff- oder Halogenatom oder ein Cyano- oder ein Alkyl- oder Alkoxyradikal mit jeweils 1 bis 4 Kohlenstoffatomen steht und p für 1, 2, oder 3 steht, oder R^6 die Formel $-NHR^7$ aufweist, worin R^7 für ein Alkylradikal mit 1 bis 10 Kohlenstoff-
10 atomen steht oder R^7 die Formel



15 aufweist, wobei m, p und R^6 die oben angegebenen Bedeutungen besitzen; oder eines pharmazeutisch zulässigen Säureadditionssalzes davon, dadurch gekennzeichnet, daß
a) entweder ein Alkenderivat der Formel




20 worin R^1 , R^2 , R^3 , R^4 und n die oben angegebenen Bedeutungen besitzen, mit einem acylierenden Derivat acyliert wird, das sich von einer Säure der Formel $R^5\text{COOH}$ ableitet, worin R^5 die oben angegebene Be-
25 deutung besitzt, oder, wenn R^5 die Formel $-NHR^7$ besitzt, dieses Alkenderivat mit einem Isocyanat der Formel $R^7\text{NCO}$ umgesetzt wird; oder
b) ein Alkanol der Formel




35 worin R^1 , R^2 , R^3 , R^4 , R^5 und n die oben angegebenen Bedeutungen besitzen, mit einer Säure de-
hydratisiert wird,
worauf das Alkenderivat in seine cis- und trans-Isomere getrennt werden kann; und
40 worauf ein Alkenderivat in der freien Basenform durch Umsetzung mit einer Säure in ein Säure-
additionssalz überführt werden kann.

2. Verfahren zur Herstellung eines Alkenderivats der Formel




worin R^1 und R^2 jeweils für das gleiche Alkylradikal mit 1 bis 4 Kohlenstoffatomen stehen, R^3 für ein Alkylradikal mit 1 bis 4 Kohlenstoffatomen steht, R^4 für Wasserstoff oder ein Halogenatom oder ein Alkylradikal mit 1 bis 4 Kohlenstoffatomen steht, R^5 für Methyl, Äthyl, Isopropyl oder Phenyl steht und n für 2, 3, 4 oder 5 steht, oder eines pharmazeutisch zulässigen Säureadditionssalzes davon, dadurch gekennzeichnet, daß ein Alkenderivat der Formel



worin R^1 , R^2 , R^3 , R^4 und n die oben angegebenen Bedeutungen besitzen, mit einem acylierenden Derivat, das sich von einer Säure der Formel $R^5\text{COOH}$ ableitet, worin R^5 die oben angegebene Bedeutung besitzt, acyliert wird, worauf das Alkenderivat in seine cis- und trans-Isomere getrennt werden kann.

Revendications pour les Etats contractants: BE CH DE FR GB IT LU NL SE

25 1. Un dérivé alcénique de formule:



dans laquelle R^1 est un atome d'hydrogène ou un radical alkyle ayant 1 à 4 atomes de carbone et R^2 est un radical alkyle ayant 1 à 4 atomes de carbone, ou bien R^1 et R^2 forment conjointement avec l'atome adjacent d'azote un radical hétérocyclique pentagonal ou hexagonal, n est égal à 2, 3, 4, 5 ou 6; R^3 est un atome d'halogène ou un radical alkyle ayant 1 à 4 atomes de carbone; R^4 est un atome d'hydrogène ou d'halogène, ou un radical hydroxy ou alkyle ou alkoxy ayant chacun 1 à 4 atomes de carbone, ou représente le radical buta-1,3-diényle de manière qu'il forme conjointement avec le noyau benzénique un radical naphthyle, ou bien R^4 répond à la formule $-\text{OCOR}^5$; et R^5 est un radical alkyle ayant 1 à 10 atomes de carbone ou un radical alkoxyalkyle ayant 2 à 10 atomes de carbone, ou bien R^5 répond à la formule:



dans laquelle m est égal à 0, 1, 2, 3 ou 4, R^6 est un atome d'hydrogène ou d'halogène ou un radical cyano ou alkyle ou alkoxy ayant chacun 1 à 4 atomes de carbone et p est égal à 1, 2 ou 3; ou bien R^5 répond à la formule $-\text{NHR}^7$ dans laquelle R^7 est un radical alkyle ayant 1 à 10 atomes de carbone, ou bien R^7 répond à la formule:



dans laquelle m , p et R^6 ont les définitions indiquées ci-dessus, ou un sel d'addition d'acide pharmaceutiquement acceptable de ce dérivé.

2. Un dérivé alcénique suivant la revendication 1, dans lequel R^1 et R^2 sont tous deux un radical méthyle ou tous deux un radical éthyle, R^3 est le radical méthyle, éthyle ou propyle, R^4 est un atome


d'hydrogène, de fluor, de chlore ou de brome ou le radical méthyle, éthyle ou méthoxy, R⁵ est le radical méthyle, éthyle, isopropyle, tertio-butyle, méthoxyméthyle, phényle, 2-tolyle, 4-tolyle, 2-éthylphényle, 2-chlorophényle, 3-chlorophényle, 4-chlorophényle, 4-bromophényle, 4-méthoxyphényle, 4-cyano-phényle, benzyle méthylamino, propylamino ou anilino et *n* est égal à 2, 3, 4 ou 5, ou un sel d'addition
5 d'acide pharmaceutiquement acceptable de ce dérivé.

3. Un dérivé alcénique suivant la revendication 2, dans lequel R¹ et R² sont tous deux un radical méthyle, R³ est le radical éthyle, R⁴ est un atome d'hydrogène ou un atome de chlore ou le radical méthyle ou éthyle en position 4, R⁵ est le radical méthyle, éthyle, isopropyle ou phényle et *n* est égal à 2, ou un sel d'addition d'acide pharmaceutiquement acceptable de ce dérivé.

10 4. Le 1-(*p*-β-diméthylaminoéthoxyphényl)-*trans*-1-*p*-acétoxyphényl-2-*p*-tolylbut-1-ène, le 1-(*p*-β-diméthylaminoéthoxyphényl)-*trans*-1-*p*-acétoxyphényl-2-phénylbut-1-ène, le 1-(*p*-β-diméthylaminoéthoxyphényl)-*trans*-1-*p*-benzoyloxyphényl-2-phénylbut-1-ène ou le 1-(*p*-β-diméthylaminoéthoxyphényl)-*trans*-1-*p*-propionyloxyphényl-2-phénylbut-1-ène.


5. Le 1-(*p*-β-diméthylaminoéthoxyphényl)-*trans*-1-*p*-acétoxyphényl-2-*p*-éthylphénylbut-1-ène ou
15 le 1-(*p*-β-diméthylaminoéthoxyphényl)-*trans*-1-*p*-benzoyloxyphényl-2-*p*-tolylbut-1-ène.

6. Procédé de production d'un dérivé alcénique suivant l'une quelconque des revendications 1 à 5 ou d'un sel d'addition d'acide pharmaceutiquement acceptable de ce dérivé, qui comprend
(a) l'acylation d'un dérivé alcénique de formule:



dans laquelle R¹, R², R³, R⁴ et *n* ont les définitions données dans la revendication 1, avec un dérivé acylant obtenu à partir d'un acide de formule R⁵COOH, dans laquelle R⁵ a la définition indiquée dans la revendication 1, ou bien, lorsque R⁵ répond à la formule —NHR⁷, la réaction dudit dérivé alcénique avec un isocyanate de formule R⁷NCO; ou

35 (b) la déshydratation d'un alcool de formule:




dans laquelle R¹, R², R³, R⁴, R⁵ et *n* ont les définitions indiquées ci-dessus, avec un acide
50 après quoi le dérivé alcénique peut être divisé en ses isomères *cis* et *trans*; puis un dérivé alcénique sous la forme de la base libre peut être converti en un sel d'addition d'acide par réaction avec un acide.

7. Composition pharmaceutique, qui comprend un dérivé alcénique ou un sel d'addition d'acide pharmaceutiquement acceptable de ce dérivé suivant l'une quelconque des revendications 1 à 5, en association avec un diluant ou excipient pharmaceutiquement acceptable.

Revendications pour l'Etat contractant: AT

1. Procédé de préparation d'un dérivé alcénique de formule:



15 dans laquelle R¹ est un atome d'hydrogène ou un radical alkyle ayant 1 à 4 atomes de carbone et R² est un radical alkyle ayant 1 à 4 atomes de carbone, ou bien R¹ et R² forment conjointement avec l'atome adjacent d'azote un radical hétérocyclique pentagonal ou hexagonal; n est égal à 2, 3, 4, 5 ou 6; R³ est un atome d'halogène ou un radical alkyle ayant 1 à 4 atomes de carbone; R⁴ est un atome d'hydrogène ou d'halogène ou un radical hydroxy ou alkyle ou alkoxy ayant chacun 1 à 4 atomes de carbone, ou

20 représente le radical buta-1,3-diényle, en sorte qu'il forme conjointement avec le noyau benzénique un radical naphthyle, ou bien R⁴ répond à la formule —OCOR⁵; et R⁵ est un radical alkyle ayant 1 à 10 atomes de carbone ou un radical alkoxyalkyle ayant 2 à 10 atomes de carbone, ou bien R⁵ répond à la

25 formule:




dans laquelle m est égal à 0, 1, 2, 3 ou 4, R⁶ est un atome d'hydrogène ou d'halogène ou un radical cyano ou alkyle ou alkoxy ayant chacun 1 à 4 atomes de carbone et p est égal à 1, 2 ou 3, ou bien R⁶ répond à la formule —NHR⁷, dans laquelle R⁷ est un radical alkyle ayant 1 à 10 atomes de carbone, ou

40 bien R⁷ répond à la formule:



dans laquelle m, p et R⁶ ont les définitions indiquées ci-dessus, ou d'un sel d'addition d'acide pharmaceutiquement acceptable de ce dérivé, caractérisé par

55 (a) l'acylation d'un dérivé alcénique de formule:




dans laquelle R¹, R², R³, R⁴ et n ont les définitions indiquées ci-dessus, avec un dérivé acylant obtenu à partir d'un acide de formule R⁵COOH, dans laquelle R⁵ a la définition donnée ci-dessus, ou bien lorsque R⁵ répond à la formule —NHR⁷, réaction dudit dérivé alcénique avec un isocyanate de formule R⁷NCO;

60 ou

(b) la déshydratation d'un alcanol de formule:


0011 372



(III)


dans laquelle R^1 , R^2 , R^3 , R^4 , R^5 et n ont les définitions indiquées ci-dessus, avec un acide, après quoi le dérivé alcénique peut être divisé en ses isomères *cis* et *trans*; puis un dérivé alcénique sous la forme de la base libre peut être converti en un sel d'addition d'acide par réaction avec un acide.

2. Procédé de préparation d'un dérivé alcénique de formule:



(I)

dans laquelle R^1 et R^2 représentent tous deux le même radical alkyle ayant 1 à 4 atomes de carbone, R^3 est un radical alkyle ayant 1 à 4 atomes de carbone, R^4 est un atome d'hydrogène ou un atome d'halogène ou un radical alkyle ayant 1 à 4 atomes de carbone, R^5 est un radical méthyle, éthyle, isopropyle ou phényle et n est égal à 2, 3, 4 ou 5, ou d'un sel d'addition d'acide pharmaceutiquement acceptable de ce dérivé, caractérisé par l'acylation d'un dérivé alcénique de formule:



(II)

dans laquelle R^1 , R^2 , R^3 , R^4 et n ont les définitions indiquées ci-dessus, avec un dérivé acylant obtenu à partir d'un acide de formule R^5COOH , dans laquelle R^5 a la définition indiquée ci-dessus, après quoi le dérivé alcénique peut être divisé en ses isomères *cis* et *trans*.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.